Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAM | P19021 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2463624 | 0.87 | PAM (0.39) | PAMMAPTKDM4ETHRBALOX15 | |
| SCHEMBL14789044 | 0.84 | PAM (0.39) | PAMMAPTKDM4ETHRBALOX15 | |
| SCHEMBL2429383 | 0.80 | KDM4E (0.36) | PAMMAPTKDM4ETHRBALOX15 | |
| SCHEMBL13179780 | 0.79 | PAM (0.36) | PAMMAPTKDM4ETHRBALOX15 | |
| SCHEMBL12308073 | 0.79 | PAM (0.34) | PAMMAPTKDM4ETHRBALOX15 | |
| SCHEMBL2429387 | 0.79 | PAM (0.37) | PAMMAPTKDM4ETHRBALOX15 | |
| SCHEMBL10564990 | 0.79 | MAPT (0.42) | PAMMAPTKDM4ETHRBALOX15 | |
| SCHEMBL13142864 | 0.78 | PAM (0.35) | PAMMAPTKDM4ETHRBALOX15 | |
| Dacisteine SCHEMBL2402188 | 0.77 | MAPT (0.55) | PAMMAPTKDM4ETHRBALOX15 | |
| Dacisteine SCHEMBL1814125 | 0.77 | MAPT (0.55) | PAMMAPTKDM4ETHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2937334-A1 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2937334-A1 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8815905-B2 | Propionic acids, propionic acid esters, and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110224156-A1 | Propionic Acids, Propionic Acid Esters, and Related Compounds | ALBANY MOLECULAR RESEARCH, INC. | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224156-A1 | Propionic Acids, Propionic Acid Esters, and Related Compounds | PCCA, PC, PMP22 | PAM 1904/4885MAPT 165/4885KDM4E 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.